1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in South Africa

Generics in South Africa

  • January 2017
  • -
  • MarketLine
  • -
  • 35 pages

Summary
Generics in South Africa industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in South Africa
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in South Africa
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the South Africa generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the South Africa generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the South Africa generics market by value in 2016?
- What will be the size of the South Africa generics market in 2021?
- What factors are affecting the strength of competition in the South Africa generics market?
- How has the market performed over the last five years?
- How large is South Africa's generics market in relation to its regional counterparts?

Key Findings
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The South African generics market is expected to generate total revenues of $637m in 2016, representing a compound annual growth rate (CAGR) of 5.9% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 3% between 2012 and 2016, to reach a total of 82.5% of total pharma volume in 2016.

The government is showing strong support for generic drugs in Africa, which should see good growth in the future. For example, pharmacists are required by law to inform private patients about generic alternatives.

Table Of Contents

Generics in South Africa
Table of Contents
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Adcock Ingram Holdings Limited
Aspen Pharmacare Holdings Ltd
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: South Africa generics market value: $ billion, 2012-16(e)
Table 2: South Africa generics market volume: % of total pharma volume, 2012-16(e)
Table 3: South Africa generics market geography segmentation: $ billion, 2016(e)
Table 4: South Africa generics market value forecast: $ billion, 2016-21
Table 5: South Africa generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Adcock Ingram Holdings Limited: key facts
Table 7: Adcock Ingram Holdings Limited: key financials ($)
Table 8: Adcock Ingram Holdings Limited: key financials (ZAR)
Table 9: Adcock Ingram Holdings Limited: key financial ratios
Table 10: Aspen Pharmacare Holdings Ltd: key facts
Table 11: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 12: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 13: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: South Africa size of population (million), 2012-16
Table 18: South Africa gdp (constant 2005 prices, $ billion), 2012-16
Table 19: South Africa gdp (current prices, $ billion), 2012-16
Table 20: South Africa inflation, 2012-16
Table 21: South Africa consumer price index (absolute), 2012-16
Table 22: South Africa exchange rate, 2012-16

List of Figures
Figure 1: South Africa generics market value: $ billion, 2012-16(e)
Figure 2: South Africa generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: South Africa generics market geography segmentation: % share, by value, 2016(e)
Figure 4: South Africa generics market value forecast: $ billion, 2016-21
Figure 5: South Africa generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in South Africa, 2016
Figure 7: Drivers of buyer power in the generics market in South Africa, 2016
Figure 8: Drivers of supplier power in the generics market in South Africa, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in South Africa, 2016
Figure 11: Drivers of degree of rivalry in the generics market in South Africa, 2016
Figure 12: Adcock Ingram Holdings Limited: revenues and profitability
Figure 13: Adcock Ingram Holdings Limited: assets and liabilities
Figure 14: Aspen Pharmacare Holdings Ltd: revenues and profitability
Figure 15: Aspen Pharmacare Holdings Ltd: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.